Poland - Pharmaceutical products

Description

The subject matter of the contract is the supply of medicinal products - 47 tasks, the detailed description of which is contained in Annexes 1-47 to the ToR - "Tender Form - Price Form". The Contracting Authority allows for partial tenders. The subject matter of the contract is 47 tasks. The Contracting Authority allows for offering different package sizes than those described in the Annexes, in which case the number of packages offered should be recalculated in such a way as to enable the execution of the entire contract. If necessary, the number of offered packages should be rounded up. The validity period of the subject of the contract (suitability for use) must be at least 12 months from the date of delivery to the headquarters of the Orderer. The contractor shall ensure the labelling of the medicinal product in accordance with the Regulation of the Minister of Health of 20.2.2009.on the requirements for the labelling of medicinal products and the content of leaflets.
Rivastigminum 3 mg, op. 28 kaps.10 op. Donepezili hydrochloridim 5 mg, op. 28 tabl 10 op. Donepezili hydrochloridim 10 mg, op. 28 tabl 10 op. Memantini hydrochloride 20 mg, op. 28 film-coated tablets 10 op. Cladribinum 1 mg/ml, solution for infusion, op. 1 vial 10 ml 105 op. Amphotericinum B 50 mg, powder for solution for infusion, op. 1 vial 50 mg + membrane filter 40 op. Telmisartanum 40 mg, op. 28 table 160 op. Telmisartanum 80 mg, op. 28 table 30 op. Rosuvastatinum 5 mg, op. 28 tabl. 50 op. Rosuvastatinum 40 mg, op. 28 tabl. 45 op. Miscellaneous pharmaceutical products - 29 items. For a detailed description see Annex 8 to the SCI Streptomycin 1.0 g vial. 20 op. Heparin+Sodium Citrate+Taurolidine 500 x 10 amp. and 5 ml 5 op. Sterile, absorbable hemostatic sponge of homogeneous porosity, for topical use in surgery accompanied by venous bleeding and drainage, size 80 x 50 x 10 mm, op. 10 pcs. 100 op. Sterile, absorbable hemostatic sponge of homogeneous porosity, for topical use in surgery accompanied by venous bleeding and drainage, size 80 x 50 x 1 mm, op. 10 pcs. 100 op. Hypoallergenic infant formula with partial hydrolysed whey protein OptiPro HA, 90 ml bottle, op. 32 bottles 200 op. Heparinum natricum 5000 IU/ml, op. 10 amp 5 ml 230 op. Various pharmaceutical products - 14 items. Detailed description can be found in Appendix 14 to the SIC Clarithromycinum 0.5 g tab. x 20 tab. 60 op. Ceftazidime pr. to inj. 2 g x 1 vial 3 500 op. Cefuroxime 0.05 g inj. op. 10 vials + 10 needles with 90 op. Various pharmaceutical products - item 11. Detailed description can be found in Annex 18 to the PIC Ertapen 1.0 g, pr. to p. solution for infusion 1 vial. 40 op. Tigecycline 0.05g, pr. to p. solution for infusion op. 10 vials. 50 op.Voriconazole 0.2g, inj. op. 1 vial + 50ml sack + accessories 210 op. Fluoresceinum 0.1 g/ml x10 amp. 5 ml 15 op. Dalteparinum natricum 2500 IU. teat size x 10 5 Op. Dalteparinum natricum 5000 IU. teat size x 10 125 Op. Dalteparinum natricum 7500 IU. teat size x 105 Op. Hepatitis B immune globulin 200j.m./ml, inj. op. 1 amp. 18 op. Miscellaneous pharmaceutical products - 63 pos. For a detailed description see Annex 24 to the SIC Pregabalinum 75 mg, op. 28 capsules 70 op. Pregabalinum 150 mg, op. 28 capsules 50 op. Human serum protein, containing: albumin, immunoglobulin G, immunoglobulin A, immunoglobulin M, solution to inf.(50 mg/ml) - 1 flacon 50 ml 25 op.Human Immunoglobulin Normal (IVIg) 50 mg/ml (at least 96 % IgG pure), vial 20 ml 15 op. Human albumin 20 % and 50 ml 3 500 op. Immunoglobulins 0.5 g/10 ml 200 op. Immunoglobulins 5 g/100 ml 10 op. Dabigatran etexilate 0.11 g x 180 caps./ 3 x 60 caps. 5 op.Dabigatran etexilate 0.15 g x 180 caps. 5 op. Clindamycinum 20 mg/g 2 % vaginal cream, op. 1 tube 40g 10 op.Clindamycinum 300mg, op. 16 capsules 260 op. Ceftazidime pr. to inj. 1 g x 1 vial. 5 000 op. Ceftriaxone inj. 1 g 1 vial. 4 000 op. Tropicamidum 1 %,(10mg/ml),eye drops,2x5ml 1 000 op. Sertindolum 4mg, op. 30 tablets 4 op. Natamycinum 100 mg globules, op. 6 pcs. 20 op. Fondaparinux 2.5 mg/0.5 ml x 10 amp. - teat. 8 Op. Superparinum calcicum 3800 IU/0.4 ml x 10 amp. - teat. 400 op.Nadroparinum calcicum 47500 IU/5 ml x 10 vials 35 op.Nadroparinum calcicum 5700 IU/0.6ml x 10 amp. - teat. 60 op.Nadroparinum calcicum 7600 IU/0.8 ml x 10 amps - teat. 15 op. Enoxaparinum natricum 0.1 g/1.0ml x 10 amp.-injection. 60 op. Enoxaparinum natricum 0.02g/0.2 ml x 10 amp.-injection. 40 op.Enoxaparinum natricum 0.04 g/0.4ml x 10 amp.-injection. 3 500 op.Enoxaparinum natricum 0.06 g/0.6ml x 10 amp.-injection. 790 op.Enoxaparinum natricum 0.08 g/0.8ml x 10 amp.-injection. 220 op.Enoxaparinum natricum 0.12 g/0.8ml x 10 amp.-injection. 5 op. Spiramycinum 1500000 IU x 16 tabl. 20 op. Teicoplaninum 0.2 g, lyophilizate for inj. x 1 vial dry 45 op. Teicoplaninum 0.4 g lyophilizate for inj. x 1 vial dry 250 op. Immunoglobulinum anti-T lymphocytorum ex animale ad usum humanum 5mg/ml powder for solution concentrate for infusion, op. 1 vial 80 I Concentrate of human prothrombin syndrome containing proteins C and S and balanced composition of clotting factors (human II blood clotting factor + human VII blood clotting factor + human IX blood clotting factor + human X blood clotting factor + protein C + protein S). Antithrombin-free III. Physically and chemically pure does not contain unnecessary substances such as human albumin and acids or bases which may adversely affect the therapy of patients. Standardization for factor IX. Specific activity ≥ 0.6 IU/mg of protein, expressed as factor IX activity. Pack of 500 IUU powder and solvent for solution for infusion. 50 op. Tobramycinum 3 mg/ml and 80 ml x 10 flasks. 5 op. Cefazolin pr. do inj. doż./dom. 1g x 1 vial. 7 000 op. Cefotaxime 1g pr. do inj. d¿d¿d¿d¿a. x 1 vial. 3 600 op. Cefuroxime 0.75 g inj. op. 1 vial. 1 900 op. Cefuroxime 1,5 g inj. op. 1 vial. 3 100 op. Tetanus immune globiulins 250 I.m./1 ml, op. 1 pre-filled syringe 10 op. Esmololol 100 mg/10 ml x 5 vial. 8 op. Erythromycinum Intraven,0.3g x 1 vial. 10 op. Erythromycinum tabl. overlay 0.2g x 16 tabl. 3 op.

Opportunity closing date

16 June 2020

Value of contract

to be confirmed